Jupiter Neurosciences, Inc. Common Stock (JUNS) is a publicly traded Healthcare sector company. As of July 7, 2026, JUNS trades at $0.21 with a market cap of $10.75M and a P/E ratio of -0.91. JUNS moved -4.48% today. Year to date, JUNS is -79.50%; over the trailing twelve months it is -86.59%. Its 52-week range spans $0.17 to $19.51. Rallies surfaces JUNS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Jupiter Neurosciences Appoints Ex-White House Advisor, Awards 536,428 Share Options: Jupiter Neurosciences appointed health economist Tomas J. Philipson to its board effective June 26, 2026, assigning him to both audit and compensation committees. He received a sign-on option for 90,000 shares and performance-aligned options for 446,428 shares valued at $125,000, tying compensation to long-term stock performance.
| Metric | Value |
|---|---|
| Price | $0.21 |
| Market Cap | $10.75M |
| P/E Ratio | -0.91 |
| EPS | $-0.25 |
| Dividend Yield | 0.00% |
| 52-Week High | $19.51 |
| 52-Week Low | $0.17 |
| Volume | 1.00M |
| Avg Volume | 0 |
| Revenue (TTM) | $21.80K |
| Net Income | $-8.64M |
| Gross Margin | 0.00% |
JUNS analyst coverage data. Average price target: $0.00.